Industry
Biotechnology
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:09 am
Portfolio Pulse from Avi Kapoor
March 25, 2024 | 12:03 pm
Portfolio Pulse from Vandana Singh
March 22, 2024 | 3:53 pm
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 3:05 pm
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 11:12 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.